Michael D. Toboni

Dr. Michael D. Toboni

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
MTMichael D. Toboni
Michael D. Toboni
ECErin K. Crane
Erin K. Crane
JBJubilee Brown
Jubilee Brown
ASAlexander Shushkevich
Alexander Shushkevich
SCSarah Chiang
Sarah Chiang
PTPremal H. Thaker
Premal H. Thaker

23 August 2018 in The Oncologist
Verified
Journal Article
Open access
PDF file
RARebecca Arend
Rebecca Arend
MTMichael D. Toboni
Michael D. Toboni
AMAllison M. Montgomery
Allison M. Montgomery
RBRobert A. Burger
Robert A. Burger
AOAlexander B. Olawaiye
Alexander B. Olawaiye
THThomas J. Herzog
Thomas J. Herzog
The treatment of metastatic and recurrent uterine leoimyosarcoma (uLMS) has evolved rapidly in the past several years. Leoimyosarcoma is extremely aggressive and responds poorly to traditional chemotherapeutics. Recent regulatory approval of novel treatment options has significantly expanded the therapeutic armamentarium, and the addition of these therapies has challenged clinicians to select and optimally sequence these new compounds. Additionally, the potential role of immunotherapy is being assessed in current uLMS clinical trials. Given the increasing number of agents available both in the U.S. and globally, a treatment template that addresses optimal sequencing based upon expert consensus would be useful. Current guidelines, although listing various options, lack granularity by line of therapy. Most patients with leiomyosarcoma, even in early stage, are treated with surgery followed by adjuvant chemotherapy despite uLMS being relatively chemoresistant. Adjuvant chemotherapy often includes the combination of gemcitabine and docetaxel with or without doxorubicin in first-line systemic therapy, but these cytotoxic agents only provide patients with advanced disease a 5-year survival <30%. This review will focus on examination of current guidelines and consensus building for optimal sequencing of systemic therapies for advanced or recurrent uLMS. Critical ongoing studies investigating novel approaches including immunotherapeutics and genetic alterations also will be discussed. Implications for Practice: Recent regulatory approval of novel treatment options has significantly expanded the therapeutic armamentarium, and the addition of these therapies has challenged clinicians to select and optimally sequence these compounds. This review will focus on examination of current guidelines and consensus building for optimal sequencing of systemic therapies for advanced or recurrent uterine leoimyosarcoma.

13 February 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Moh'd KhushmanMoh'd Khushman
Moh'd Khushman
MTMichael D. Toboni
Michael D. Toboni
JXJoanne Xiu
Joanne Xiu
Upender ManneUpender Manne
Upender Manne
AFAlex Farrell
Alex Farrell
MPMatthew A. Powell
Matthew A. Powell
Purpose: The response to immune checkpoint inhibitors (ICI) in deficient mismatch repair (dMMR) colorectal cancer and endometrial cancer is variable. Here, we explored the differential response to ICIs according to different mismatch repair alterations Experimental Design: Colorectal cancer (N = 13,701) and endometrial cancer (N = 3,315) specimens were tested at Caris Life Sciences. Median overall survival (mOS) was estimated using Kaplan–Meier. The prediction of high-, intermediate-, and low-affinity epitopes by tumor mutation burden (TMB) values was conducted using R-squared (R2). Results: Compared with mutL (MLH1 and PMS2) co-loss, the mOS was longer in mutS (MSH2 and MSH6) co-loss in all colorectal cancer (54.6 vs. 36 months; P = 0.0.025) and endometrial cancer (81.5 vs. 48.2 months; P < 0.001) patients. In ICI-treated patients, the mOS was longer in mutS co-loss in colorectal cancer [not reached (NR) vs. 36 months; P = 0.011). In endometrial cancer, the mOS was NR vs. 42.2 months; P = 0.711]. The neoantigen load (NAL) in mutS co-loss compared with mutL co-loss was higher in colorectal cancer (high-affinity epitopes: 25.5 vs. 19; q = 0.017, intermediate: 39 vs. 32; q = 0.004, low: 87.5 vs. 73; q < 0.001) and endometrial cancer (high-affinity epitopes: 15 vs. 11; q = 0.002, intermediate: 27.5 vs. 19; q < 0.001, low: 59 vs. 41; q < 0.001), respectively. R2 ranged from 0.25 in mutS co-loss colorectal cancer to 0.95 in mutL co-loss endometrial cancer. Conclusions: Patients with mutS co-loss experienced longer mOS in colorectal cancer and endometrial cancer and better response to ICIs in colorectal cancer. Among all explored biomarkers, NAL was higher in mutS co-loss and may be a potential driving factor for the observed better outcomes. TMB did not reliably predict NAL.

1 October 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
ASAlexander Shushkevich
Alexander Shushkevich
PTPremal H. Thaker
Premal H. Thaker
RLRamey D. Littell
Ramey D. Littell
NSNaishadh A. Shah
Naishadh A. Shah
SCSarah Chiang
Sarah Chiang
JBJubilee Brown
Jubilee Brown

1 May 2016 in Menopause
Verified
Journal Article
Open access
KMKoji Matsuo
Koji Matsuo
MGMarc R. Gualtieri
Marc R. Gualtieri
SCSigita S. Cahoon
Sigita S. Cahoon
MTMichael D. Toboni
Michael D. Toboni
HMHiroko Machida
Hiroko Machida
LRLynda D. Roman
Lynda D. Roman
Objective: The aim of the study was to examine contributing factors associated with developing menopausal symptoms after surgical staging in women with endometrial cancer. Methods: This is a retrospective study examining patients with endometrial cancer who were premenopausal at the time of hysterectomy-based surgical staging including bilateral oophorectomy between January 2000 and October 2013. Cox proportional hazard regression model was used to evaluate demographics, medical comorbidity, liver function tests, tumor factors, and medication history for menopausal symptoms. Results: There were 269 premenopausal women who were eligible. Mean age was 44.5 years, and the majority had endometrioid histology (91.1%), grade 1 tumor (60.2%), and stage I disease (65.8%). Postoperatively, 73 (27.1%) women developed menopausal symptoms, with hot flushes (20.1%) being the most common symptom followed by night sweats (4.1%). On multivariate analysis, younger age was independently associated with increased risk of developing menopausal symptoms (hazard ratio per unit 0.91, 95% CI 0.88-0.94, P < 0.01). In addition, lower albumin level remained an independent predictor for decreased risk of developing menopausal symptoms (hazard ratio per unit 2.16, 95% CI 1.19-3.93, P = 0.012). Lower albumin level was associated with medical comorbidity (hypertension and diabetes mellitus), use of antihypertensive/glycemic agents (angiotensin-converting enzyme inhibitors or receptor blocker, hydrochlorothiazide, sulfonylurea, and insulin), aggressive tumor (high cancer antigen 125 level, nonendometrioid histology, and advanced stage), and abnormal liver function (high alkaline phosphatase level and low total protein level; all, P < 0.05). Conclusions: Assessing albumin level, medical comorbidity, and medication type for the development of postoperative menopausal symptoms is a valuable step in the preoperative management of women with endometrial cancer.

4 November 2021 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
MTMichael D. Toboni
Michael D. Toboni
MPMatthew A. Powell
Matthew A. Powell